Drug Trial Radar · NCT07930520
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jan 25, 2027
Primary completion
Dec 28, 2028
Study completion Dec 28, 2028
Sponsor
- Lead sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of S247240 in male participants with Fragile X Syndrome aged 18 to 45 years old. Participants will participate for 14 weeks of treatment. The study is also intended to characterize the PK profile of S247240 and to obtain preliminary assessments of the efficacy of S247240 in mental status examination scales and tests over the 14 weeks of treatment period.
Conditions
- Fragile X Syndrome (FXS)
Interventions
S247240 Low doseDrug
Participants will receive a liquid solution of S247240 low dose, to be taken orally twice daily.
S247240 Middle doseDrug
Participants will receive a liquid solution of S247240 middle dose, to be taken orally twice daily.
S247240 High doseDrug
Participants will receive a liquid solution of S247240 high dose, to be taken orally twice daily.
PlaceboOther
Participants will receive a liquid solution containing no active drug, to be taken orally twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AEs)Time frame: Through Week 16
- Severity of AEsTime frame: Through Week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.